Hyperthermia Cancer Treatment involves applying heat at the targeted area of the tumor to destroy and kill cancer cells. It works on the principle that heat can be used to damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation and certain anticancer drugs. During hyperthermia therapy, the region of the body containing the tumor is heated to temperatures slightly higher than normal body temperature but not high enough to damage healthy tissues. Hyperthermia can be regional and involve heating a specific area of the body containing tumors, whole body hyperthermia when the entire body is heated, or local hyperthermia which involves delivering heat directly to a tumor.

The Global Hyperthermia Cancer Treatment Market is estimated to be valued at US$ 215.49 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Hyperthermia Cancer Treatment are Allergan plc. (A subsidiary of AbbVie Inc.),Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, GSK plc., AstraZeneca., Baxter, Novartis AG, F. Hoffmann-La Roche Limited, Shire (A subsidiary of Takeda Pharmaceutical Company Limited) and Sanofi. Hyperthermia in combination with chemotherapy or radiation therapy can significantly improve outcomes. However, technical limitations and lack of standardization have limited its widespread clinical adoption. The increasing incidences of cancer cases across the globe is expected to drive the demand for hyperthermia cancer treatment in the upcoming years.

Due to rising cases of cancer, huge investments in R&D and advancement in the technology related to hyperthermia, the global hyperthermia cancer treatment market is expected to witness a significant growth over the forecast period. North America dominated the global market in 2020 owing to high prevalence of cancer and presence of advanced healthcare facilities. However, Asia Pacific region is expected to grow at a high CAGR during the forecast period with increasing adoption of developed technologies and rising healthcare expenditure.

Market drivers

The increasing prevalence of cancer across the globe is a major driver for the Hyperthermia Cancer Treatment Market Size. According to the WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 alone. It is estimated that there were over 19 million new cancer cases in 2020. The rising geriatric population coupled with the changing lifestyle leading to high incidence of obesity and smoking increase the risk of developing cancer, thereby driving the adoption of hyperthermia cancer treatment over the forecast period. Additionally, technological advancement in hyperthermia cancer treatment and increasing R&D investments by key players for development of efficient treatment options are further propelling the market growth.

The ongoing conflict between Russia and Ukraine is impacting growth in the hyperthermia cancer treatment market. The sanctions and trade restrictions imposed on Russia are hampering procurement of necessary medical technologies and supplies needed for hyperthermia therapy. This is posing challenges for treatment availability in Russia and other CIS countries. Additionally, the recent escalation in tensions between China and Taiwan may impact Taiwan's exports of hyperthermia devices in Asia Pacific region if a conflict breaks out. Due to the devastating consequences of war, healthcare budgets and resources in conflict affected countries are being diverted from cancer care to emergency medical aid. This is detrimental for utilization of hyperthermia technology in such regions in the short to medium term. However, manufacturers are exploring opportunities through humanitarian aid programs to deliver essential devices to hospitals in Ukraine and other east European nations. Additionally, regional alliances are being strengthened to reduce import dependence of crucial medical goods on single markets to mitigate risks of supply disruption in future conflicts. The hyperthermia cancer treatment industry will need to adopt strategies such as forging strategic partnerships, local manufacturing and stockpiling to ensure treatment access is least impacted even during heightened geopolitical volatility.

North America currently accounts for the largest share of the global hyperthermia cancer treatment market in terms of value. This is attributed to factors such as supportive reimbursement policies, rising healthcare spending, strategic initiatives by regional market players and growing adoption among hospitals and cancer care centers in the US and Canada. However, Asia Pacific is projected to emerge as the fastest growing regional market over the forecast period driven by increasing incidence of cancer, improving access to advanced treatment technologies, rising medical tourism and favorable government policies promoting hyperthermia in countries like China, India and Japan.

The Asia Pacific region offers immense growth potential for the hyperthermia cancer treatment market. Factors such as rising healthcare expenditures, expanding medical insurance coverage, increasing incidence of cancer due to lifestyle changes and rapidly developing healthcare technologies are pushing adoption of advanced treatment modalities like hyperthermia in Asia Pacific countries. Governments across the region have implemented initiatives to modernize cancer care infrastructure and make high-quality treatment more affordable and accessible to general population. This is boosting procurement of hyperthermia devices, consumables and services across hospitals, cancer centers and specialty clinics. Market players are also strategically focusing on Asia Pacific through partnerships, localized manufacturing plants and marketing initiatives to tap into the long-term opportunities in this high-growth region.